Ignyta Is Proof That Biotech Bargains Still Exist

Ignyta Is Proof That Biotech Bargains Still Exist


Trading near its all-time low Ignyta has an advanced pipeline, hoard of cash, best-in-class drug Entrectinib entering registrational clinical trial and a high probability of partnering. With the biotech sector becoming red hot again it can be hard for investors to find stocks with significant upside.



from Biotech News